NCT05800418已完成1 期
Phase I Clinical Study of Single-center, Randomized, Double-blind, Single-dose, Parallel Comparison of the Pharmacokinetics and Safety of Ramucirumab Injection and Cyramza® in Healthy Male Volunteers
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 88
- 试验地点
- 1
- 主要终点
- Area under drug concentration - time curve (AUC0-t)
研究概览
简要总结
Ramucirumab is a biosimilar drug of CYRAMZA® produced by Chiatai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., LTD. It is a vascular endothelial growth factor receptor 2 (VEGFR-2) antagonist. This single-center, randomized, double-blind, single-dose, parallel phase I study of Ramucirumab injection versus Cyramza ® in healthy male volunteers was designed to evaluate the similarities in pharmacokinetics, tolerance, safety and immunogenicity of Ramucirumab and CYRAMZA®.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Sign informed consent form before the study and fully understand the study content, process and possible adverse reactions;
- •Be able to complete the study according to the requirements of the test plan;
- •Male subjects aged 18-65 years (included);
- •The subject should weigh at least 50kg. Body mass index (BMI) = weight (kg)/ height2(m2), BMI in the range of 19 to 26 (included);
- •Health status: no mental abnormality, no medical history of abnormal cardiovascular system, nervous system, respiratory system, digestive system, urinary system, endocrine system and metabolism;
- •Normal or abnormal vital signs, physical examination, laboratory examination, electrocardiogram and imaging examination with no clinical significance;
- •Have no pregnancy plan and voluntarily take effective contraception measures from 2 weeks before the study drug administration to at least 6 months after the last dose.
排除标准
- •Have a history of neuropsychiatric system, respiratory system, cardiovascular system, digestive system, hemolymph system, liver and kidney insufficiency, endocrine system, skeletal and musculoskeletal system disease or other diseases, and the investigators judge that this history may affect drug metabolism or safety;
- •Known allergic to Ramucirumab or its excipients; Known history of allergic diseases or allergic constitution;
- •History of hypertension or abnormal blood pressure at screening/baseline measurement (systolic blood pressure (SBP) > 140 mmHg, and/or diastolic blood pressure (DBP) >90 mmHg, confirmed by one repeat measurement on the same day);
- •A history of clinically significant albuminuria (urine routine examination, albuminuria 2+ and above) or albuminuria as assessed by the investigator;
- •Had received treatment of Ramucirumab or VEGFR2 receptor antagonist, or other antibody or protein drugs that target VEGFR2 receptor;
- •Had received any live viral vaccine within 2 months prior to study drug infusion, or required vaccination between the screening period and the end of the study, had used any monoclonal antibody or biologic drug within 12 months prior to study drug administration, or planned to receive any monoclonal antibody or biologic drug within 12 months after study drug administration;
- •had unhealed wound ulcers or fractures, or had undergone major surgery within 3 months prior to study drug infusion or expected to undergo major surgery during the study period or within 2 months after study completion;
- •had taken any prescription drugs, over-the-counter drugs, any vitamin products, or herbs within 14 days prior to use of the study drug;
- •Patients with abnormal examinations and clinical significance during the screening period;
- •Blood donation or significant blood loss within 3 months prior to use of the study drug (>450 mL);
- •Have taken the study drug or participated in any clinical trial of the drug within 3 months prior to the use of the study drug;
- •Smokers who smoked more than 5 cigarettes a day in the 3 months before the test;
- •Test positive for alcohol or have a history of alcohol abuse (14 units of alcohol per week: 1 unit =360 mL of beer or 45 mL of 40% spirits or 150 mL of wine);
- •Test positive for drugs or have a history of drug abuse in the past five years or have used drugs in the three months prior to the test;
- •Hepatitis (including hepatitis B and C), AIDS, syphilis positive screening;
- •Patients with difficulty in venous blood collection or who cannot tolerate venipuncture;
- •Unable or unable to comply with ward management regulations, poor compliance during the study, or unable to follow protocol requirements to complete the study;
- •Subjects unable to complete the experiment due to personal reasons;
- •Conditions considered unsuitable for inclusion by other researchers.
研究组 & 干预措施
Ramucirumab injection
Experimental
8mg/kg, Single intravenous infusion
干预措施: Ramucirumab Injection (Drug)
Cyramza
Active Comparator
8mg/kg, Single intravenous infusion
干预措施: Ramucirumab Injection [Cyramza] (Drug)
结局指标
主要结局
Area under drug concentration - time curve (AUC0-t)
时间窗: Within 60 minutes before administration to 1680 hours after administration.
Area under the curve from zero to the lowest detectable blood drug concentration.
次要结局
- Area under drug concentration - time curve (AUC0-∞)(Within 60 minutes before administration to 1680 hours after administration.)
- Peak concentration (Cmax)(Within 60 minutes before administration to 1680 hours after administration.)
- Clearance rate (CL)(Within 60 minutes before administration to 1680 hours after administration.)
- Peak concentration time (Tmax)(Within 60 minutes before administration to 1680 hours after administration.)
- Half-life (T1/2)(Within 60 minutes before administration to 1680 hours after administration.)
- Apparent volume of distribution (Vd)(Within 60 minutes before administration to 1680 hours after administration.)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study of Ramucirumab (LY3009806) in Children With Refractory Solid TumorsPediatric Solid TumorRefractory TumorRecurrent TumorCNS MalignanciesNCT02564198Eli Lilly and Company29
已完成
1 期
A Study of Ramucirumab Combination Therapy in Japanese Participants Who Have Advanced Stomach CancerStomach NeoplasmsNCT02359058Eli Lilly and Company18
已完成
3 期
A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal CancerGastroesophageal Junction AdenocarcinomaGastric AdenocarcinomaNCT02898077Eli Lilly and Company440
已完成
1 期
A Study of Ramucirumab (LY3009806) in Healthy ParticipantsHealthyNCT04495478Eli Lilly and Company50
已完成
3 期
A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-FetoproteinHepatocellular CarcinomaNCT02435433Eli Lilly and Company399